Amid the news explosion that followed President Trump’s COVID-19 diagnosis and brief convalescence earlier this month, there was a nugget you might have missed: The antibody treatment from biotech company Regeneron the president took—seemingly to great effect—had been developed in part by means of cells derived from fetal tissue.
Want to see more of The Dispatch in Google search?
Add Us as a Preferred Source



